Save time, refresh your knowledge, and on-board your colleagues using the resource pages provided here. Check out our drug discovery resources page for a high-level overview of resources available.
-
- Approval Reviews
2022 Drug Approvals
This resource page compiles all of the 2022 drug approvals and our articles on the novel small molecule and…2 mins read
-
- Reference
- Sponsored
Phase I Drug Metabolism
This article explains what Phase I drug metabolism is, contains a poster summarizing common enzyme-mediated drug metabolism reactions, and…11 mins read
-
- Approval Reviews
2021 Large Molecule Drug Approvals Review
together with Jen Huen, Naveed Yasin, Becca Burnham, Arathi Chintireddy, and Adrian Parodi This high-level overview of 2021’s novel…2 mins read
-
- Approval Reviews
2021 Small Molecule Drug Approvals Review
We’ll be reviewing 2021’s novel FDA drug approvals in a series of articles, starting with this high-level overview of…3 mins read
-
- Approval Reviews
The Resurgence of Antibody-Drug Conjugates – FDA Approved ADCs and Linker-Payloads
Antibody-drug conjugates (ADCs) have gone through several waves of enthusiasm since being first tested in animal models in the 1960’s. The…3 mins read
-
- Industry Reviews
First Disclosures of Small Molecule Drug Candidates – EFMC-ISMC 2021
By Christian Kuttruff and Julien Lefranc The first disclosures of new drug candidates are always the highlight of medicinal…8 mins read
-
- Industry Reviews
Scientific Highlights from 2020’s Drug Discovery Biotech IPOs
Recently, our team at Drug Hunter compiled the lead programs and mechanisms of small molecule and large molecule biotechs that IPO’d in 2020. We asked featured…10 mins read
-
- Industry Reviews
2020 Biotech IPOs – Small Molecule R&D Companies
Looking at the pipelines of recent biotech IPOs is a great way to get a snapshot of new technologies…1 min read
-
- Industry Reviews
2020 Biotech IPOs – Large Molecule R&D Companies
Browsing through the pipelines of recent biotech IPOs is great way to catch up on emerging targets, novel drug…2 mins read
RECENT ARTICLES
- Small Molecule and Biotechnology-Based Therapeutics for Neurology-Focused Companies: 2021’s IPOs Part V
- Agile Drug Hunting
- Lenacapavir Synthesis Highlights
- June 2022 Molecules of the Month Runners-Up
- Molecules of the Month – June 2022
- Beginning with the End in Mind: Five Minutes with a Commercial Leader
DRUG DISCOVERY RESOURCES
- Drug Discovery Resources
- Drug Discovery Posters and Cheat Sheets
- Drug Discovery IPOs and Industry Reviews
- Lists of Approved Drugs
- Classics in Drug Discovery
- Drug Discovery Books
- Drug Discovery Conferences
- What is a Drug Hunter?
- Topliss Tree and Topliss Scheme Posters
- PK Reference Table / Cheat Sheet
- Pd-Couplings Table / Cheat Sheet
- Phase I Drug Metabolism
- Approved Covalent Drug Mechanisms
- Why LogD Matters / LogD Poster
- Types of Kinase Inhibitors
- Unusual Molecular Interactions from the PDB
- Bioactivation of Structural Alerts
- The Square Cube Law
- Don’t Work on Things That Don’t Work
- What is a Biologic Drug Anyway?
- Managing Liver Injury (DILI) Risk
- Where Do Hits Come From?
JOIN SUBSCRIBERS from
- Johnson & Johnson
- Roche
- Pfizer
- Novartis
- Bayer
- Merck
- Sanofi
- GlaxoSmithKline
- AbbVie
- Eli Lilly
- Boehringer Ingelheim
- Amgen
- Bristol-Myers Squibb
- Gilead
- AstraZeneca
- Teva
- Novo Nordisk
- Merck KGaA
- Takeda
- Celgene (BMS)
- Biogen
- Astellas
- Daiichi Sankyo
- Regeneron
- UCB
- Eisai
- Servier
- Kyowa Kirin
- Shionogi
- Vertex
- Lundbeck
- Taisho
- Ono
- Seagen
- Incyte
- LEO Pharma
- Janssen
- Galapagos
- Idorsia
- Astex
- Arvinas
- Kymera
- Relay
- Schrodinger
- Mirati
- Revolution
- Nimbus
- Plexxikon
- Forma
- Arcus
- RA Capital
- ARCH Venture Partners
- MPM Capital
- Orbimed
- The Column Group
- 5AM Ventures
- Versant Ventures
- Deerfield
- Goldman Sachs
- Citi
- Piper Sandler
- Softbank
- …and hundreds of others